Related Experiment Video
Updated: May 22, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Inflammatory breast cancer response to modern neoadjuvant chemotherapy: Tumor response and survival outcomes
Dorsa Mousa-Doust1, Amy Bazzarelli2, Melina Deban3
1Division of General Surgery, Department of Surgery, Faculty of Medicine, University of British Columbia, 2775 Laurel Street, 11th Floor, Vancouver, BC, V5Z 1M9, Canada.
Background:
Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer. This study evaluates oncologic outcomes in IBC patients treated with modern multimodal treatment.
Methods:
A retrospective review analyzed clinicopathologic data of 5063 patients, 646 of whom underwent NAC followed by surgery between 2012 and 2024. Survival outcomes were compared across biologic subtypes.
Results:
Twenty-six cases of T4dM0 IBC were identified, with 57.7 % HER-2 positive, 26.9 % ER positive/HER-2 negative, and 15.4 % ER negative/HER-2 negative. The total pCR rate was highest in HER-2 positive (53.3 %) and lowest in ER-positive/HER-2 negative patients (p = 0.036). Among 19 patients with ≥3 years of follow-up, 47 % experienced recurrence (78 % distant and 22 % locoregional) and 42 % died of breast cancer. No significant differences in locoregional recurrence, or survival outcomes were found across subtypes.
Conclusion:
pCR has limited prognostic value in IBC. Although HER-2 positive patients are more likely to achieve pCR, this does not necessarily translate into improved outcomes.
More Related Videos
07:15A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Related Concept Videos
01:27Tumor Immunotherapy
01:21Cancer Survival Analysis
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
02:17The Tumor Microenvironment
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...